Top Page
MPS Limited
(MPSLTD)
MPS Limited (MPSLTD) vs. iShares MSCI India ETF (INDA)
MPS Limited Business Overview & Revenue Model
MPS Limited Financial Statement Overview
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.32B | 7.27B | 5.45B | 5.01B | 4.46B | 4.23B |
| Gross Profit | 3.26B | 2.57B | 5.45B | 5.01B | 4.46B | 4.22B |
| EBITDA | 2.27B | 2.23B | 1.82B | 1.67B | 1.40B | 1.16B |
| Net Income | 1.58B | 1.49B | 1.19B | 1.09B | 871.21M | 585.60M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 6.95B | 7.37B | 5.52B | 4.97B | 5.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.06B | 1.45B | 1.85B | 1.38B | 1.11B |
| Total Debt | 0.00 | 36.90M | 45.41M | 75.80M | 119.85M | 183.50M |
| Total Liabilities | -4.78B | 2.17B | 2.77B | 1.33B | 1.30B | 1.26B |
| Stockholders Equity | 4.78B | 4.78B | 4.60B | 4.24B | 3.67B | 3.81B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 946.70M | 1.14B | 1.08B | 1.10B | 926.28M |
| Operating Cash Flow | 0.00 | 1.01B | 1.18B | 1.13B | 1.14B | 993.72M |
| Investing Cash Flow | 0.00 | -57.70M | 251.37M | -647.40M | 153.59M | -592.89M |
| Financing Cash Flow | 0.00 | -1.40B | -933.65M | -701.00M | -1.16B | -529.34M |
MPS Limited Technical Analysis
MPS Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹24.98B | 14.73 | ― | 4.14% | 16.76% | 50.15% | |
73 Outperform | ₹48.19B | 5.78 | ― | 7.35% | -3.25% | 60.80% | |
68 Neutral | ₹55.03B | 35.56 | ― | 0.25% | 13.96% | 31.69% | |
63 Neutral | ₹19.80B | 24.84 | ― | 1.37% | -2.79% | -26.28% | |
60 Neutral | ₹18.27B | 17.29 | ― | ― | 3.88% | -3.40% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% |
MPS Limited Corporate Events
MPS Limited has completed the acquisition of Unbound Medicine, Inc. in the U.S. through its wholly owned subsidiary, MPS North America LLC, following the execution of a stock purchase agreement signed on January 30, 2026. The deal, valued at USD 16.50 million subject to customary adjustments, gives MPS NA LLC 100% ownership of Unbound Medicine and converts the U.S. firm into a wholly owned step-down subsidiary of MPS Limited.
The transaction closed after satisfaction of customary conditions, with the full completion consideration paid at closing as per the agreed terms. The acquisition strengthens MPS Limited’s operational footprint in North America and signals a deeper push into technology-driven, specialized content offerings for healthcare and related professional markets, with potential implications for the company’s growth trajectory and competitive positioning in global knowledge services.
MPS Limited has scheduled a conference call on 18 February 2026 to discuss its acquisition of U.S.-based Unbound Medicine Inc. The call will be led by Chairman and CEO Rahul Arora, alongside the senior management team, and will be accessible to investors via universal and toll-free dial-in numbers and an online Diamond Pass link.
The company is using the call to brief investors and stakeholders on the strategic rationale and details of the Unbound Medicine transaction, underlining the importance of the deal for its North American operations. By formally engaging the market through this dedicated event, MPS signals that the acquisition is a significant step in its growth agenda and could shape its competitive position in digital medical and professional content services.
MPS Limited has detailed the funding structure for its wholly owned subsidiary MPS North America LLC’s proposed USD 16.5 million acquisition of US-based Unbound Medicine, Inc. The deal will be financed through a mix of internal accruals, inter-company loans, and external borrowing, including a USD 3 million loan from subsidiary American Journal Experts, a USD 1.94 million loan from MPS Limited, and a proposed INR 420 million term loan from ICICI Bank that will support an equity infusion of around USD 9.81 million into MPS North America LLC. The subsidiary will remain 100% owned by MPS before and after the equity infusion, and the company emphasized that all funding arrangements and any additional minor inter-company loans from group entities will comply with Indian foreign exchange and overseas investment regulations. The structured financing underlines MPS’s capital deployment strategy for overseas acquisitions and signals a continued push to expand its presence in specialized digital and medical information markets without diluting ownership in its key North American arm.
MPS North America LLC, a wholly owned subsidiary of MPS Limited, has signed a stock purchase agreement to acquire 100% of Unbound Medicine, Inc., a U.S.-based healthcare learning technology company, for USD 16.5 million, subject to customary adjustments. Unbound Medicine, which generated USD 8.88 million in revenue in 2024, provides mobile-first, AI-enabled clinical decision-support and medical education platforms to more than 480 institutional customers, including medical schools, hospital systems and healthcare associations across the U.S. and Canada, largely on a subscription model with high retention rates. The deal marks MPS’s formal entry into the healthcare and medical information technology segment, aligning with its strategy to pivot toward scalable, profitable businesses and supporting its long-term goal of surpassing INR 1,500 crore in revenue by FY28, while broadening its customer base into critical healthcare and medical education segments and strengthening its recurring revenue profile.
MPS North America LLC, the wholly owned U.S. subsidiary of MPS Limited, has agreed to acquire a 100% stake in Unbound Medicine, Inc., a U.S.-based provider of digital medical reference, clinical decision-support, and healthcare learning solutions that serves medical schools, hospital systems, and professional associations across the United States and Canada via mobile-first and web-based platforms. The deal marks MPS Limited’s entry into the healthcare and medical information technology segment and is positioned as a transformative strategic milestone, expected to diversify revenue, deepen the company’s presence in the North American market, unlock cross-selling and AI-driven innovation opportunities, and strengthen its role as a technology-first partner to the global healthcare community.
MPS Limited has responded to a query from the National Stock Exchange of India regarding a recent sharp increase in trading volume in its shares, stating that it is not aware of any undisclosed information or impending announcements that could explain the price or volume movement. The company emphasized that any spurt in price or volume is purely market-driven, and reiterated that it has been regularly disclosing all required price-sensitive information under SEBI’s Listing Obligations and Disclosure Requirements, signaling that there is no insider or undisclosed corporate development behind the recent trading activity.
MPS Limited conducted an earnings conference call to discuss its unaudited financial results for the second quarter and half-year ending September 30, 2025. The call, led by key management figures, highlighted the company’s financial performance and strategic initiatives. The release of these results is crucial for stakeholders as it provides insights into the company’s operational efficiency and market strategy, potentially impacting its industry positioning.